nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—pancreatic cancer—colon cancer	0.258	0.553	CtDrD
Erlotinib—lung cancer—colon cancer	0.208	0.447	CtDrD
Erlotinib—EGFR—colon cancer	0.178	0.767	CbGaD
Erlotinib—ABCB1—colon cancer	0.0542	0.233	CbGaD
Erlotinib—UGT1A1—Irinotecan—colon cancer	0.0278	0.18	CbGbCtD
Erlotinib—ABCG2—Irinotecan—colon cancer	0.0153	0.0989	CbGbCtD
Erlotinib—ABCG2—Fluorouracil—colon cancer	0.0147	0.0949	CbGbCtD
Erlotinib—ABCG2—Vincristine—colon cancer	0.0134	0.0864	CbGbCtD
Erlotinib—ALB—Irinotecan—colon cancer	0.0106	0.0682	CbGbCtD
Erlotinib—ALB—Fluorouracil—colon cancer	0.0101	0.0654	CbGbCtD
Erlotinib—CYP3A5—Irinotecan—colon cancer	0.00848	0.0548	CbGbCtD
Erlotinib—ABCG2—Methotrexate—colon cancer	0.0081	0.0523	CbGbCtD
Erlotinib—CYP2C8—Fluorouracil—colon cancer	0.00783	0.0505	CbGbCtD
Erlotinib—CYP3A5—Vincristine—colon cancer	0.00741	0.0479	CbGbCtD
Erlotinib—CYP1A2—Fluorouracil—colon cancer	0.00606	0.0391	CbGbCtD
Erlotinib—ALB—Methotrexate—colon cancer	0.00558	0.0361	CbGbCtD
Erlotinib—ABCB1—Irinotecan—colon cancer	0.00552	0.0357	CbGbCtD
Erlotinib—ABCB1—Vincristine—colon cancer	0.00482	0.0312	CbGbCtD
Erlotinib—CYP3A4—Irinotecan—colon cancer	0.00331	0.0214	CbGbCtD
Erlotinib—ABCB1—Methotrexate—colon cancer	0.00292	0.0189	CbGbCtD
Erlotinib—CYP3A4—Vincristine—colon cancer	0.00289	0.0187	CbGbCtD
Erlotinib—ORM1—bile—colon cancer	0.00213	0.0717	CbGeAlD
Erlotinib—ABL1—Topotecan—Irinotecan—colon cancer	0.00134	1	CbGdCrCtD
Erlotinib—NR1I2—digestive system—colon cancer	0.00076	0.0256	CbGeAlD
Erlotinib—Vandetanib—SRC—colon cancer	0.000741	0.303	CrCbGaD
Erlotinib—JAK3—lymphoid tissue—colon cancer	0.000615	0.0207	CbGeAlD
Erlotinib—JAK3—digestive system—colon cancer	0.000608	0.0205	CbGeAlD
Erlotinib—ORM1—gall bladder—colon cancer	0.000591	0.0199	CbGeAlD
Erlotinib—Vandetanib—VEGFA—colon cancer	0.00059	0.241	CrCbGaD
Erlotinib—NR1I2—liver—colon cancer	0.000567	0.0191	CbGeAlD
Erlotinib—ALB—gall bladder—colon cancer	0.000518	0.0174	CbGeAlD
Erlotinib—Vandetanib—EGFR—colon cancer	0.000498	0.204	CrCbGaD
Erlotinib—TNK1—vagina—colon cancer	0.000493	0.0166	CbGeAlD
Erlotinib—FLT3—lymphoid tissue—colon cancer	0.000485	0.0164	CbGeAlD
Erlotinib—Gefitinib—EGFR—colon cancer	0.000473	0.193	CrCbGaD
Erlotinib—FLT3—bone marrow—colon cancer	0.000442	0.0149	CbGeAlD
Erlotinib—LTK—lymph node—colon cancer	0.000434	0.0146	CbGeAlD
Erlotinib—TNK1—liver—colon cancer	0.000416	0.014	CbGeAlD
Erlotinib—ULK3—digestive system—colon cancer	0.000414	0.0139	CbGeAlD
Erlotinib—ABL2—vagina—colon cancer	0.000404	0.0136	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—colon cancer	0.000399	0.0135	CbGeAlD
Erlotinib—MKNK1—lymphoid tissue—colon cancer	0.000394	0.0133	CbGeAlD
Erlotinib—STK10—renal system—colon cancer	0.000391	0.0132	CbGeAlD
Erlotinib—MKNK1—digestive system—colon cancer	0.000389	0.0131	CbGeAlD
Erlotinib—PIP4K2C—vagina—colon cancer	0.000383	0.0129	CbGeAlD
Erlotinib—ULK3—bone marrow—colon cancer	0.000381	0.0128	CbGeAlD
Erlotinib—AURKC—lymph node—colon cancer	0.000375	0.0126	CbGeAlD
Erlotinib—UGT1A1—renal system—colon cancer	0.000369	0.0124	CbGeAlD
Erlotinib—ULK3—vagina—colon cancer	0.000365	0.0123	CbGeAlD
Erlotinib—MKNK1—bone marrow—colon cancer	0.000359	0.0121	CbGeAlD
Erlotinib—FLT3—liver—colon cancer	0.000357	0.012	CbGeAlD
Erlotinib—ABL1—embryo—colon cancer	0.000356	0.012	CbGeAlD
Erlotinib—JAK3—lymph node—colon cancer	0.000347	0.0117	CbGeAlD
Erlotinib—MKNK1—vagina—colon cancer	0.000344	0.0116	CbGeAlD
Erlotinib—ABL2—liver—colon cancer	0.000341	0.0115	CbGeAlD
Erlotinib—SLK—bone marrow—colon cancer	0.00034	0.0114	CbGeAlD
Erlotinib—EGFR—liver—colon cancer	0.000333	0.0112	CbGeAlD
Erlotinib—SLK—vagina—colon cancer	0.000326	0.011	CbGeAlD
Erlotinib—STK10—lymphoid tissue—colon cancer	0.000325	0.0109	CbGeAlD
Erlotinib—PIP4K2C—liver—colon cancer	0.000323	0.0109	CbGeAlD
Erlotinib—STK10—digestive system—colon cancer	0.000321	0.0108	CbGeAlD
Erlotinib—TNK1—lymph node—colon cancer	0.000319	0.0107	CbGeAlD
Erlotinib—ULK3—liver—colon cancer	0.000308	0.0104	CbGeAlD
Erlotinib—UGT1A1—digestive system—colon cancer	0.000303	0.0102	CbGeAlD
Erlotinib—STK10—bone marrow—colon cancer	0.000296	0.00996	CbGeAlD
Erlotinib—MKNK1—liver—colon cancer	0.00029	0.00977	CbGeAlD
Erlotinib—STK10—vagina—colon cancer	0.000283	0.00954	CbGeAlD
Erlotinib—ABL1—smooth muscle tissue—colon cancer	0.00028	0.00942	CbGeAlD
Erlotinib—SLK—liver—colon cancer	0.000275	0.00925	CbGeAlD
Erlotinib—FLT3—lymph node—colon cancer	0.000274	0.00923	CbGeAlD
Erlotinib—SLCO2B1—renal system—colon cancer	0.000272	0.00915	CbGeAlD
Erlotinib—ABL1—renal system—colon cancer	0.000269	0.00907	CbGeAlD
Erlotinib—ABL2—lymph node—colon cancer	0.000262	0.00881	CbGeAlD
Erlotinib—EGFR—lymph node—colon cancer	0.000255	0.0086	CbGeAlD
Erlotinib—MAP2K5—vagina—colon cancer	0.000253	0.00852	CbGeAlD
Erlotinib—PIP4K2C—lymph node—colon cancer	0.000247	0.00834	CbGeAlD
Erlotinib—STK10—liver—colon cancer	0.000239	0.00805	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—colon cancer	0.000237	0.00798	CbGeAlD
Erlotinib—ULK3—lymph node—colon cancer	0.000236	0.00796	CbGeAlD
Erlotinib—CYP1B1—renal system—colon cancer	0.000228	0.00768	CbGeAlD
Erlotinib—UGT1A1—liver—colon cancer	0.000226	0.0076	CbGeAlD
Erlotinib—ABL1—lymphoid tissue—colon cancer	0.000224	0.00753	CbGeAlD
Erlotinib—SLCO2B1—digestive system—colon cancer	0.000223	0.00751	CbGeAlD
Erlotinib—MKNK1—lymph node—colon cancer	0.000222	0.00749	CbGeAlD
Erlotinib—ABL1—digestive system—colon cancer	0.000221	0.00744	CbGeAlD
Erlotinib—ORM1—bone marrow—colon cancer	0.000214	0.00722	CbGeAlD
Erlotinib—MAP2K5—liver—colon cancer	0.000213	0.00719	CbGeAlD
Erlotinib—SLK—lymph node—colon cancer	0.000211	0.00709	CbGeAlD
Erlotinib—ABL1—bone marrow—colon cancer	0.000204	0.00686	CbGeAlD
Erlotinib—ABL1—vagina—colon cancer	0.000195	0.00657	CbGeAlD
Erlotinib—CYP1B1—lymphoid tissue—colon cancer	0.000189	0.00638	CbGeAlD
Erlotinib—CYP1B1—digestive system—colon cancer	0.000187	0.0063	CbGeAlD
Erlotinib—ABCB1—blood vessel—colon cancer	0.000185	0.00625	CbGeAlD
Erlotinib—STK10—lymph node—colon cancer	0.000183	0.00617	CbGeAlD
Erlotinib—CYP2C8—renal system—colon cancer	0.000175	0.00588	CbGeAlD
Erlotinib—CYP1A1—epithelium—colon cancer	0.000174	0.00585	CbGeAlD
Erlotinib—ORM1—liver—colon cancer	0.000173	0.00583	CbGeAlD
Erlotinib—SLCO2B1—liver—colon cancer	0.000166	0.00559	CbGeAlD
Erlotinib—ABL1—liver—colon cancer	0.000165	0.00554	CbGeAlD
Erlotinib—MAP2K5—lymph node—colon cancer	0.000164	0.00551	CbGeAlD
Erlotinib—CYP1A2—renal system—colon cancer	0.000163	0.00551	CbGeAlD
Erlotinib—CYP1A1—renal system—colon cancer	0.000161	0.00543	CbGeAlD
Erlotinib—CYP3A5—renal system—colon cancer	0.000158	0.00531	CbGeAlD
Erlotinib—Pneumonia—Fluorouracil—colon cancer	0.000152	0.00232	CcSEcCtD
Erlotinib—ALB—liver—colon cancer	0.000152	0.00512	CbGeAlD
Erlotinib—Haemolytic anaemia—Capecitabine—colon cancer	0.000152	0.00232	CcSEcCtD
Erlotinib—Infestation NOS—Fluorouracil—colon cancer	0.000151	0.00231	CcSEcCtD
Erlotinib—Infestation—Fluorouracil—colon cancer	0.000151	0.00231	CcSEcCtD
Erlotinib—Acute coronary syndrome—Fluorouracil—colon cancer	0.000149	0.00228	CcSEcCtD
Erlotinib—Renal failure acute—Capecitabine—colon cancer	0.000148	0.00227	CcSEcCtD
Erlotinib—Myocardial infarction—Fluorouracil—colon cancer	0.000148	0.00227	CcSEcCtD
Erlotinib—Neuropathy peripheral—Fluorouracil—colon cancer	0.000148	0.00227	CcSEcCtD
Erlotinib—Stomatitis—Fluorouracil—colon cancer	0.000147	0.00225	CcSEcCtD
Erlotinib—Conjunctivitis—Fluorouracil—colon cancer	0.000147	0.00225	CcSEcCtD
Erlotinib—Inflammation—Methotrexate—colon cancer	0.000145	0.00222	CcSEcCtD
Erlotinib—Renal impairment—Capecitabine—colon cancer	0.000144	0.0022	CcSEcCtD
Erlotinib—Gefitinib—ABCB1—colon cancer	0.000144	0.0588	CrCbGaD
Erlotinib—Urinary tract disorder—Vincristine—colon cancer	0.000144	0.0022	CcSEcCtD
Erlotinib—Dermatitis bullous—Capecitabine—colon cancer	0.000143	0.00219	CcSEcCtD
Erlotinib—Connective tissue disorder—Vincristine—colon cancer	0.000143	0.00219	CcSEcCtD
Erlotinib—Urethral disorder—Vincristine—colon cancer	0.000143	0.00218	CcSEcCtD
Erlotinib—Epistaxis—Fluorouracil—colon cancer	0.000143	0.00218	CcSEcCtD
Erlotinib—Haemoglobin—Irinotecan—colon cancer	0.000142	0.00218	CcSEcCtD
Erlotinib—Haemorrhage—Irinotecan—colon cancer	0.000142	0.00217	CcSEcCtD
Erlotinib—Cerebrovascular accident—Capecitabine—colon cancer	0.00014	0.00214	CcSEcCtD
Erlotinib—CYP1B1—liver—colon cancer	0.000139	0.00469	CbGeAlD
Erlotinib—Connective tissue disorder—Irinotecan—colon cancer	0.000139	0.00213	CcSEcCtD
Erlotinib—Melaena—Methotrexate—colon cancer	0.000137	0.0021	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.000137	0.0021	CcSEcCtD
Erlotinib—Haemoglobin—Fluorouracil—colon cancer	0.000136	0.00209	CcSEcCtD
Erlotinib—Haemorrhage—Fluorouracil—colon cancer	0.000136	0.00208	CcSEcCtD
Erlotinib—Skin exfoliation—Methotrexate—colon cancer	0.000134	0.00205	CcSEcCtD
Erlotinib—CYP1A2—digestive system—colon cancer	0.000134	0.00452	CbGeAlD
Erlotinib—ORM1—lymph node—colon cancer	0.000133	0.00447	CbGeAlD
Erlotinib—CYP1A1—digestive system—colon cancer	0.000132	0.00445	CbGeAlD
Erlotinib—Mediastinal disorder—Vincristine—colon cancer	0.000131	0.00201	CcSEcCtD
Erlotinib—CYP3A5—digestive system—colon cancer	0.000129	0.00436	CbGeAlD
Erlotinib—Alopecia—Vincristine—colon cancer	0.000129	0.00197	CcSEcCtD
Erlotinib—ABCG2—bone marrow—colon cancer	0.000128	0.00433	CbGeAlD
Erlotinib—Mediastinal disorder—Irinotecan—colon cancer	0.000128	0.00195	CcSEcCtD
Erlotinib—Dehydration—Capecitabine—colon cancer	0.000127	0.00195	CcSEcCtD
Erlotinib—Mental disorder—Vincristine—colon cancer	0.000127	0.00195	CcSEcCtD
Erlotinib—SLCO2B1—lymph node—colon cancer	0.000127	0.00429	CbGeAlD
Erlotinib—Chills—Irinotecan—colon cancer	0.000127	0.00194	CcSEcCtD
Erlotinib—Arrhythmia—Irinotecan—colon cancer	0.000127	0.00194	CcSEcCtD
Erlotinib—CYP2C8—vagina—colon cancer	0.000126	0.00426	CbGeAlD
Erlotinib—ABL1—lymph node—colon cancer	0.000126	0.00425	CbGeAlD
Erlotinib—Dry skin—Capecitabine—colon cancer	0.000126	0.00192	CcSEcCtD
Erlotinib—Alopecia—Irinotecan—colon cancer	0.000125	0.00191	CcSEcCtD
Erlotinib—Hypokalaemia—Capecitabine—colon cancer	0.000125	0.00191	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.000123	0.00189	CcSEcCtD
Erlotinib—ABCG2—vagina—colon cancer	0.000123	0.00414	CbGeAlD
Erlotinib—Back pain—Vincristine—colon cancer	0.000122	0.00187	CcSEcCtD
Erlotinib—Sepsis—Methotrexate—colon cancer	0.000122	0.00187	CcSEcCtD
Erlotinib—Flatulence—Irinotecan—colon cancer	0.000122	0.00186	CcSEcCtD
Erlotinib—Gastritis—Capecitabine—colon cancer	0.000121	0.00186	CcSEcCtD
Erlotinib—Arrhythmia—Fluorouracil—colon cancer	0.000121	0.00185	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000121	0.00185	CcSEcCtD
Erlotinib—Alopecia—Fluorouracil—colon cancer	0.00012	0.00183	CcSEcCtD
Erlotinib—Back pain—Irinotecan—colon cancer	0.000119	0.00182	CcSEcCtD
Erlotinib—Dysphagia—Capecitabine—colon cancer	0.000118	0.00181	CcSEcCtD
Erlotinib—CYP3A4—renal system—colon cancer	0.000118	0.00399	CbGeAlD
Erlotinib—Erythema—Fluorouracil—colon cancer	0.000118	0.00181	CcSEcCtD
Erlotinib—CYP1A1—vagina—colon cancer	0.000117	0.00393	CbGeAlD
Erlotinib—ALB—lymph node—colon cancer	0.000116	0.00392	CbGeAlD
Erlotinib—CYP2D6—renal system—colon cancer	0.000116	0.00392	CbGeAlD
Erlotinib—CYP3A5—vagina—colon cancer	0.000114	0.00385	CbGeAlD
Erlotinib—Hepatic failure—Methotrexate—colon cancer	0.000114	0.00174	CcSEcCtD
Erlotinib—Neutropenia—Capecitabine—colon cancer	0.000111	0.00169	CcSEcCtD
Erlotinib—ABCB1—embryo—colon cancer	0.000111	0.00373	CbGeAlD
Erlotinib—Syncope—Irinotecan—colon cancer	0.000111	0.00169	CcSEcCtD
Erlotinib—Renal failure acute—Methotrexate—colon cancer	0.00011	0.00169	CcSEcCtD
Erlotinib—Loss of consciousness—Irinotecan—colon cancer	0.000108	0.00166	CcSEcCtD
Erlotinib—Myalgia—Vincristine—colon cancer	0.000108	0.00165	CcSEcCtD
Erlotinib—Cough—Irinotecan—colon cancer	0.000108	0.00165	CcSEcCtD
Erlotinib—Weight decreased—Capecitabine—colon cancer	0.000107	0.00164	CcSEcCtD
Erlotinib—CYP1B1—lymph node—colon cancer	0.000107	0.0036	CbGeAlD
Erlotinib—CYP2C8—liver—colon cancer	0.000107	0.0036	CbGeAlD
Erlotinib—Pneumonia—Capecitabine—colon cancer	0.000106	0.00162	CcSEcCtD
Erlotinib—Infestation NOS—Capecitabine—colon cancer	0.000106	0.00162	CcSEcCtD
Erlotinib—Infestation—Capecitabine—colon cancer	0.000106	0.00162	CcSEcCtD
Erlotinib—Depression—Capecitabine—colon cancer	0.000105	0.00161	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000105	0.0016	CcSEcCtD
Erlotinib—Acute coronary syndrome—Capecitabine—colon cancer	0.000104	0.00159	CcSEcCtD
Erlotinib—Cerebrovascular accident—Methotrexate—colon cancer	0.000104	0.00159	CcSEcCtD
Erlotinib—Renal failure—Capecitabine—colon cancer	0.000104	0.00159	CcSEcCtD
Erlotinib—ABCG2—liver—colon cancer	0.000104	0.0035	CbGeAlD
Erlotinib—Myocardial infarction—Capecitabine—colon cancer	0.000104	0.00158	CcSEcCtD
Erlotinib—Neuropathy peripheral—Capecitabine—colon cancer	0.000104	0.00158	CcSEcCtD
Erlotinib—Oedema—Vincristine—colon cancer	0.000103	0.00158	CcSEcCtD
Erlotinib—Stomatitis—Capecitabine—colon cancer	0.000103	0.00157	CcSEcCtD
Erlotinib—Infection—Vincristine—colon cancer	0.000103	0.00157	CcSEcCtD
Erlotinib—Conjunctivitis—Capecitabine—colon cancer	0.000103	0.00157	CcSEcCtD
Erlotinib—Nervous system disorder—Vincristine—colon cancer	0.000101	0.00155	CcSEcCtD
Erlotinib—Thrombocytopenia—Vincristine—colon cancer	0.000101	0.00155	CcSEcCtD
Erlotinib—Oedema—Irinotecan—colon cancer	0.000101	0.00154	CcSEcCtD
Erlotinib—Myalgia—Fluorouracil—colon cancer	0.000101	0.00154	CcSEcCtD
Erlotinib—Chest pain—Fluorouracil—colon cancer	0.000101	0.00154	CcSEcCtD
Erlotinib—Infection—Irinotecan—colon cancer	0.0001	0.00153	CcSEcCtD
Erlotinib—Hepatobiliary disease—Capecitabine—colon cancer	9.99e-05	0.00153	CcSEcCtD
Erlotinib—CYP1A2—liver—colon cancer	9.99e-05	0.00336	CbGeAlD
Erlotinib—Epistaxis—Capecitabine—colon cancer	9.96e-05	0.00152	CcSEcCtD
Erlotinib—Shock—Irinotecan—colon cancer	9.9e-05	0.00151	CcSEcCtD
Erlotinib—Nervous system disorder—Irinotecan—colon cancer	9.87e-05	0.00151	CcSEcCtD
Erlotinib—Thrombocytopenia—Irinotecan—colon cancer	9.85e-05	0.00151	CcSEcCtD
Erlotinib—CYP1A1—liver—colon cancer	9.85e-05	0.00332	CbGeAlD
Erlotinib—Anorexia—Vincristine—colon cancer	9.85e-05	0.00151	CcSEcCtD
Erlotinib—CYP3A4—digestive system—colon cancer	9.7e-05	0.00327	CbGeAlD
Erlotinib—Oedema—Fluorouracil—colon cancer	9.64e-05	0.00147	CcSEcCtD
Erlotinib—CYP3A5—liver—colon cancer	9.63e-05	0.00324	CbGeAlD
Erlotinib—Anorexia—Irinotecan—colon cancer	9.59e-05	0.00147	CcSEcCtD
Erlotinib—Infection—Fluorouracil—colon cancer	9.58e-05	0.00146	CcSEcCtD
Erlotinib—CYP2D6—digestive system—colon cancer	9.55e-05	0.00322	CbGeAlD
Erlotinib—Haemoglobin—Capecitabine—colon cancer	9.53e-05	0.00146	CcSEcCtD
Erlotinib—Hepatitis—Capecitabine—colon cancer	9.48e-05	0.00145	CcSEcCtD
Erlotinib—Haemorrhage—Capecitabine—colon cancer	9.48e-05	0.00145	CcSEcCtD
Erlotinib—Nervous system disorder—Fluorouracil—colon cancer	9.45e-05	0.00145	CcSEcCtD
Erlotinib—Thrombocytopenia—Fluorouracil—colon cancer	9.44e-05	0.00144	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Vincristine—colon cancer	9.41e-05	0.00144	CcSEcCtD
Erlotinib—Urinary tract disorder—Capecitabine—colon cancer	9.36e-05	0.00143	CcSEcCtD
Erlotinib—Insomnia—Vincristine—colon cancer	9.35e-05	0.00143	CcSEcCtD
Erlotinib—Connective tissue disorder—Capecitabine—colon cancer	9.32e-05	0.00142	CcSEcCtD
Erlotinib—Urethral disorder—Capecitabine—colon cancer	9.29e-05	0.00142	CcSEcCtD
Erlotinib—Anorexia—Fluorouracil—colon cancer	9.19e-05	0.00141	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Methotrexate—colon cancer	9.19e-05	0.00141	CcSEcCtD
Erlotinib—Insomnia—Irinotecan—colon cancer	9.1e-05	0.00139	CcSEcCtD
Erlotinib—ABCB1—epithelium—colon cancer	9.03e-05	0.00304	CbGeAlD
Erlotinib—Decreased appetite—Vincristine—colon cancer	8.98e-05	0.00137	CcSEcCtD
Erlotinib—Dyspnoea—Irinotecan—colon cancer	8.97e-05	0.00137	CcSEcCtD
Erlotinib—Erythema multiforme—Capecitabine—colon cancer	8.96e-05	0.00137	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Vincristine—colon cancer	8.92e-05	0.00136	CcSEcCtD
Erlotinib—Fatigue—Vincristine—colon cancer	8.91e-05	0.00136	CcSEcCtD
Erlotinib—Eye disorder—Capecitabine—colon cancer	8.86e-05	0.00136	CcSEcCtD
Erlotinib—Dyspepsia—Irinotecan—colon cancer	8.86e-05	0.00135	CcSEcCtD
Erlotinib—Constipation—Vincristine—colon cancer	8.84e-05	0.00135	CcSEcCtD
Erlotinib—Pain—Vincristine—colon cancer	8.84e-05	0.00135	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Fluorouracil—colon cancer	8.78e-05	0.00134	CcSEcCtD
Erlotinib—Decreased appetite—Irinotecan—colon cancer	8.75e-05	0.00134	CcSEcCtD
Erlotinib—Insomnia—Fluorouracil—colon cancer	8.72e-05	0.00133	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Irinotecan—colon cancer	8.69e-05	0.00133	CcSEcCtD
Erlotinib—Fatigue—Irinotecan—colon cancer	8.68e-05	0.00133	CcSEcCtD
Erlotinib—Pancreatitis—Methotrexate—colon cancer	8.64e-05	0.00132	CcSEcCtD
Erlotinib—Constipation—Irinotecan—colon cancer	8.61e-05	0.00132	CcSEcCtD
Erlotinib—Pain—Irinotecan—colon cancer	8.61e-05	0.00132	CcSEcCtD
Erlotinib—Dyspnoea—Fluorouracil—colon cancer	8.59e-05	0.00131	CcSEcCtD
Erlotinib—Mediastinal disorder—Capecitabine—colon cancer	8.54e-05	0.00131	CcSEcCtD
Erlotinib—Chills—Capecitabine—colon cancer	8.51e-05	0.0013	CcSEcCtD
Erlotinib—Dyspepsia—Fluorouracil—colon cancer	8.48e-05	0.0013	CcSEcCtD
Erlotinib—Arrhythmia—Capecitabine—colon cancer	8.47e-05	0.0013	CcSEcCtD
Erlotinib—Gastrointestinal pain—Vincristine—colon cancer	8.45e-05	0.00129	CcSEcCtD
Erlotinib—Decreased appetite—Fluorouracil—colon cancer	8.38e-05	0.00128	CcSEcCtD
Erlotinib—Alopecia—Capecitabine—colon cancer	8.38e-05	0.00128	CcSEcCtD
Erlotinib—ABCB1—renal system—colon cancer	8.37e-05	0.00282	CbGeAlD
Erlotinib—Gastrointestinal disorder—Fluorouracil—colon cancer	8.32e-05	0.00127	CcSEcCtD
Erlotinib—Mental disorder—Capecitabine—colon cancer	8.31e-05	0.00127	CcSEcCtD
Erlotinib—Malnutrition—Capecitabine—colon cancer	8.25e-05	0.00126	CcSEcCtD
Erlotinib—Erythema—Capecitabine—colon cancer	8.25e-05	0.00126	CcSEcCtD
Erlotinib—Neutropenia—Methotrexate—colon cancer	8.24e-05	0.00126	CcSEcCtD
Erlotinib—Pain—Fluorouracil—colon cancer	8.24e-05	0.00126	CcSEcCtD
Erlotinib—Gastrointestinal pain—Irinotecan—colon cancer	8.23e-05	0.00126	CcSEcCtD
Erlotinib—Body temperature increased—Vincristine—colon cancer	8.17e-05	0.00125	CcSEcCtD
Erlotinib—Abdominal pain—Vincristine—colon cancer	8.17e-05	0.00125	CcSEcCtD
Erlotinib—Flatulence—Capecitabine—colon cancer	8.13e-05	0.00124	CcSEcCtD
Erlotinib—Back pain—Capecitabine—colon cancer	7.98e-05	0.00122	CcSEcCtD
Erlotinib—Body temperature increased—Irinotecan—colon cancer	7.96e-05	0.00122	CcSEcCtD
Erlotinib—Abdominal pain—Irinotecan—colon cancer	7.96e-05	0.00122	CcSEcCtD
Erlotinib—ABCG2—lymph node—colon cancer	7.96e-05	0.00268	CbGeAlD
Erlotinib—Pneumonia—Methotrexate—colon cancer	7.91e-05	0.00121	CcSEcCtD
Erlotinib—Infestation—Methotrexate—colon cancer	7.86e-05	0.0012	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—colon cancer	7.86e-05	0.0012	CcSEcCtD
Erlotinib—Depression—Methotrexate—colon cancer	7.84e-05	0.0012	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—colon cancer	7.79e-05	0.00119	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—colon cancer	7.73e-05	0.00118	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—colon cancer	7.66e-05	0.00117	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—colon cancer	7.64e-05	0.00117	CcSEcCtD
Erlotinib—Body temperature increased—Fluorouracil—colon cancer	7.62e-05	0.00117	CcSEcCtD
Erlotinib—CYP1A1—lymph node—colon cancer	7.55e-05	0.00254	CbGeAlD
Erlotinib—Hepatobiliary disease—Methotrexate—colon cancer	7.43e-05	0.00114	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—colon cancer	7.41e-05	0.00113	CcSEcCtD
Erlotinib—Asthenia—Vincristine—colon cancer	7.41e-05	0.00113	CcSEcCtD
Erlotinib—Syncope—Capecitabine—colon cancer	7.4e-05	0.00113	CcSEcCtD
Erlotinib—Loss of consciousness—Capecitabine—colon cancer	7.25e-05	0.00111	CcSEcCtD
Erlotinib—CYP3A4—liver—colon cancer	7.23e-05	0.00244	CbGeAlD
Erlotinib—Asthenia—Irinotecan—colon cancer	7.22e-05	0.0011	CcSEcCtD
Erlotinib—Cough—Capecitabine—colon cancer	7.2e-05	0.0011	CcSEcCtD
Erlotinib—CYP2D6—liver—colon cancer	7.11e-05	0.0024	CbGeAlD
Erlotinib—Haemoglobin—Methotrexate—colon cancer	7.09e-05	0.00108	CcSEcCtD
Erlotinib—Diarrhoea—Vincristine—colon cancer	7.07e-05	0.00108	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—colon cancer	7.06e-05	0.00108	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—colon cancer	7.06e-05	0.00108	CcSEcCtD
Erlotinib—Chest pain—Capecitabine—colon cancer	7.03e-05	0.00107	CcSEcCtD
Erlotinib—Arthralgia—Capecitabine—colon cancer	7.03e-05	0.00107	CcSEcCtD
Erlotinib—Myalgia—Capecitabine—colon cancer	7.03e-05	0.00107	CcSEcCtD
Erlotinib—Anxiety—Capecitabine—colon cancer	7e-05	0.00107	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	6.98e-05	0.00107	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—colon cancer	6.97e-05	0.00107	CcSEcCtD
Erlotinib—ABCB1—lymphoid tissue—colon cancer	6.95e-05	0.00234	CbGeAlD
Erlotinib—Urethral disorder—Methotrexate—colon cancer	6.92e-05	0.00106	CcSEcCtD
Erlotinib—Diarrhoea—Irinotecan—colon cancer	6.89e-05	0.00105	CcSEcCtD
Erlotinib—ABCB1—digestive system—colon cancer	6.87e-05	0.00231	CbGeAlD
Erlotinib—Dizziness—Vincristine—colon cancer	6.83e-05	0.00105	CcSEcCtD
Erlotinib—Pruritus—Fluorouracil—colon cancer	6.82e-05	0.00104	CcSEcCtD
Erlotinib—Oedema—Capecitabine—colon cancer	6.74e-05	0.00103	CcSEcCtD
Erlotinib—Infection—Capecitabine—colon cancer	6.69e-05	0.00102	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—colon cancer	6.67e-05	0.00102	CcSEcCtD
Erlotinib—Dizziness—Irinotecan—colon cancer	6.65e-05	0.00102	CcSEcCtD
Erlotinib—Shock—Capecitabine—colon cancer	6.63e-05	0.00101	CcSEcCtD
Erlotinib—Nervous system disorder—Capecitabine—colon cancer	6.6e-05	0.00101	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—colon cancer	6.6e-05	0.00101	CcSEcCtD
Erlotinib—Diarrhoea—Fluorouracil—colon cancer	6.59e-05	0.00101	CcSEcCtD
Erlotinib—Thrombocytopenia—Capecitabine—colon cancer	6.59e-05	0.00101	CcSEcCtD
Erlotinib—Vomiting—Vincristine—colon cancer	6.57e-05	0.001	CcSEcCtD
Erlotinib—Skin disorder—Capecitabine—colon cancer	6.54e-05	0.001	CcSEcCtD
Erlotinib—Rash—Vincristine—colon cancer	6.52e-05	0.000997	CcSEcCtD
Erlotinib—Dermatitis—Vincristine—colon cancer	6.51e-05	0.000996	CcSEcCtD
Erlotinib—Headache—Vincristine—colon cancer	6.47e-05	0.00099	CcSEcCtD
Erlotinib—Anorexia—Capecitabine—colon cancer	6.42e-05	0.000982	CcSEcCtD
Erlotinib—Vomiting—Irinotecan—colon cancer	6.4e-05	0.000979	CcSEcCtD
Erlotinib—Dizziness—Fluorouracil—colon cancer	6.37e-05	0.000975	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—colon cancer	6.36e-05	0.000973	CcSEcCtD
Erlotinib—Rash—Irinotecan—colon cancer	6.35e-05	0.000971	CcSEcCtD
Erlotinib—Dermatitis—Irinotecan—colon cancer	6.34e-05	0.00097	CcSEcCtD
Erlotinib—Chills—Methotrexate—colon cancer	6.33e-05	0.000969	CcSEcCtD
Erlotinib—ABCB1—bone marrow—colon cancer	6.33e-05	0.00213	CbGeAlD
Erlotinib—Headache—Irinotecan—colon cancer	6.3e-05	0.000964	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—colon cancer	6.24e-05	0.000954	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—colon cancer	6.18e-05	0.000946	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—colon cancer	6.14e-05	0.00094	CcSEcCtD
Erlotinib—Erythema—Methotrexate—colon cancer	6.14e-05	0.00094	CcSEcCtD
Erlotinib—Nausea—Vincristine—colon cancer	6.14e-05	0.000939	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Capecitabine—colon cancer	6.14e-05	0.000939	CcSEcCtD
Erlotinib—Vomiting—Fluorouracil—colon cancer	6.13e-05	0.000937	CcSEcCtD
Erlotinib—Insomnia—Capecitabine—colon cancer	6.09e-05	0.000932	CcSEcCtD
Erlotinib—Rash—Fluorouracil—colon cancer	6.08e-05	0.00093	CcSEcCtD
Erlotinib—Dermatitis—Fluorouracil—colon cancer	6.07e-05	0.000929	CcSEcCtD
Erlotinib—ABCB1—vagina—colon cancer	6.06e-05	0.00204	CbGeAlD
Erlotinib—Headache—Fluorouracil—colon cancer	6.04e-05	0.000924	CcSEcCtD
Erlotinib—Dyspnoea—Capecitabine—colon cancer	6e-05	0.000918	CcSEcCtD
Erlotinib—Nausea—Irinotecan—colon cancer	5.98e-05	0.000914	CcSEcCtD
Erlotinib—Back pain—Methotrexate—colon cancer	5.94e-05	0.000909	CcSEcCtD
Erlotinib—Dyspepsia—Capecitabine—colon cancer	5.93e-05	0.000907	CcSEcCtD
Erlotinib—Decreased appetite—Capecitabine—colon cancer	5.85e-05	0.000896	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Capecitabine—colon cancer	5.81e-05	0.000889	CcSEcCtD
Erlotinib—Fatigue—Capecitabine—colon cancer	5.81e-05	0.000888	CcSEcCtD
Erlotinib—Pain—Capecitabine—colon cancer	5.76e-05	0.000881	CcSEcCtD
Erlotinib—Constipation—Capecitabine—colon cancer	5.76e-05	0.000881	CcSEcCtD
Erlotinib—Nausea—Fluorouracil—colon cancer	5.72e-05	0.000876	CcSEcCtD
Erlotinib—Gastrointestinal pain—Capecitabine—colon cancer	5.51e-05	0.000842	CcSEcCtD
Erlotinib—Cough—Methotrexate—colon cancer	5.36e-05	0.00082	CcSEcCtD
Erlotinib—Body temperature increased—Capecitabine—colon cancer	5.32e-05	0.000814	CcSEcCtD
Erlotinib—Abdominal pain—Capecitabine—colon cancer	5.32e-05	0.000814	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—colon cancer	5.23e-05	0.0008	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—colon cancer	5.23e-05	0.0008	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—colon cancer	5.23e-05	0.0008	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	5.19e-05	0.000795	CcSEcCtD
Erlotinib—ABCB1—liver—colon cancer	5.12e-05	0.00172	CbGeAlD
Erlotinib—Infection—Methotrexate—colon cancer	4.98e-05	0.000762	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—colon cancer	4.92e-05	0.000752	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—colon cancer	4.91e-05	0.000751	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—colon cancer	4.87e-05	0.000745	CcSEcCtD
Erlotinib—Asthenia—Capecitabine—colon cancer	4.83e-05	0.000739	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—colon cancer	4.78e-05	0.000731	CcSEcCtD
Erlotinib—Pruritus—Capecitabine—colon cancer	4.77e-05	0.000729	CcSEcCtD
Erlotinib—Diarrhoea—Capecitabine—colon cancer	4.61e-05	0.000705	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—colon cancer	4.57e-05	0.000699	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—colon cancer	4.53e-05	0.000694	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—colon cancer	4.47e-05	0.000684	CcSEcCtD
Erlotinib—Dizziness—Capecitabine—colon cancer	4.45e-05	0.000681	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—colon cancer	4.41e-05	0.000675	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—colon cancer	4.36e-05	0.000667	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—colon cancer	4.33e-05	0.000662	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—colon cancer	4.32e-05	0.000661	CcSEcCtD
Erlotinib—Pain—Methotrexate—colon cancer	4.29e-05	0.000656	CcSEcCtD
Erlotinib—Vomiting—Capecitabine—colon cancer	4.28e-05	0.000655	CcSEcCtD
Erlotinib—Rash—Capecitabine—colon cancer	4.25e-05	0.00065	CcSEcCtD
Erlotinib—Dermatitis—Capecitabine—colon cancer	4.24e-05	0.000649	CcSEcCtD
Erlotinib—Headache—Capecitabine—colon cancer	4.22e-05	0.000645	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—colon cancer	4.1e-05	0.000627	CcSEcCtD
Erlotinib—Nausea—Capecitabine—colon cancer	4e-05	0.000612	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—colon cancer	3.96e-05	0.000606	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—colon cancer	3.96e-05	0.000606	CcSEcCtD
Erlotinib—ABCB1—lymph node—colon cancer	3.92e-05	0.00132	CbGeAlD
Erlotinib—Asthenia—Methotrexate—colon cancer	3.6e-05	0.00055	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—colon cancer	3.55e-05	0.000543	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—colon cancer	3.43e-05	0.000525	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—colon cancer	3.32e-05	0.000507	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—colon cancer	3.19e-05	0.000488	CcSEcCtD
Erlotinib—Rash—Methotrexate—colon cancer	3.16e-05	0.000484	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—colon cancer	3.16e-05	0.000483	CcSEcCtD
Erlotinib—Headache—Methotrexate—colon cancer	3.14e-05	0.00048	CcSEcCtD
Erlotinib—Nausea—Methotrexate—colon cancer	2.98e-05	0.000456	CcSEcCtD
Erlotinib—EGFR—Innate Immune System—CDKN1A—colon cancer	5.44e-06	0.000113	CbGpPWpGaD
Erlotinib—EGFR—Immune System—BCL2L1—colon cancer	5.44e-06	0.000113	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—KRAS—colon cancer	5.42e-06	0.000112	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—BRAF—colon cancer	5.41e-06	0.000112	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	5.4e-06	0.000112	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.37e-06	0.000111	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ABCB1—colon cancer	5.26e-06	0.000109	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CDKN1A—colon cancer	5.23e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FGFR3—colon cancer	5.2e-06	0.000108	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—EP300—colon cancer	5.18e-06	0.000107	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—colon cancer	5.17e-06	0.000107	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—colon cancer	5.17e-06	0.000107	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TYMS—colon cancer	5.16e-06	0.000107	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MYC—colon cancer	5.15e-06	0.000107	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDH1—colon cancer	5.15e-06	0.000107	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TGFB1—colon cancer	5.14e-06	0.000107	CbGpPWpGaD
Erlotinib—MKNK1—Disease—AKT1—colon cancer	5.1e-06	0.000106	CbGpPWpGaD
Erlotinib—JAK3—Immune System—PIK3CA—colon cancer	5.1e-06	0.000106	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TGFB1—colon cancer	5.1e-06	0.000106	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	5.1e-06	0.000106	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	5.06e-06	0.000105	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—colon cancer	5.04e-06	0.000104	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—SRC—colon cancer	5.04e-06	0.000104	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—AKT1—colon cancer	5.02e-06	0.000104	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—PIK3CA—colon cancer	4.98e-06	0.000103	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CASP3—colon cancer	4.98e-06	0.000103	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KRAS—colon cancer	4.88e-06	0.000101	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—AKT1—colon cancer	4.87e-06	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NRAS—colon cancer	4.85e-06	0.0001	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCND1—colon cancer	4.84e-06	0.0001	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—SRC—colon cancer	4.84e-06	0.0001	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—colon cancer	4.82e-06	9.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—FGFR3—colon cancer	4.8e-06	9.96e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CTNNB1—colon cancer	4.8e-06	9.94e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ABCB1—colon cancer	4.78e-06	9.91e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KRAS—colon cancer	4.76e-06	9.87e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	4.76e-06	9.86e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—KRAS—colon cancer	4.72e-06	9.79e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—colon cancer	4.72e-06	9.78e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TYMS—colon cancer	4.7e-06	9.74e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—colon cancer	4.7e-06	9.73e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CDKN1A—colon cancer	4.69e-06	9.71e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.68e-06	9.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NRAS—colon cancer	4.65e-06	9.64e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.64e-06	9.61e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	4.61e-06	9.56e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—colon cancer	4.61e-06	9.55e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—AKT1—colon cancer	4.56e-06	9.45e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	4.53e-06	9.39e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—PIK3CA—colon cancer	4.48e-06	9.29e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EP300—colon cancer	4.46e-06	9.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—APC—colon cancer	4.41e-06	9.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDH1—colon cancer	4.4e-06	9.11e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PIK3CA—colon cancer	4.37e-06	9.06e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SRC—colon cancer	4.34e-06	8.99e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—colon cancer	4.23e-06	8.77e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—colon cancer	4.22e-06	8.75e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NRAS—colon cancer	4.17e-06	8.64e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—colon cancer	4.17e-06	8.64e-05	CbGpPWpGaD
Erlotinib—JAK3—Immune System—AKT1—colon cancer	4.17e-06	8.64e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—colon cancer	4.15e-06	8.6e-05	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—AKT1—colon cancer	4.15e-06	8.6e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—BRAF—colon cancer	4.15e-06	8.59e-05	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—AKT1—colon cancer	4.07e-06	8.43e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CASP3—colon cancer	4.06e-06	8.41e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—colon cancer	4.05e-06	8.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—colon cancer	4.01e-06	8.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—colon cancer	4e-06	8.3e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.98e-06	8.25e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	3.98e-06	8.24e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCND1—colon cancer	3.95e-06	8.18e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PPARG—colon cancer	3.92e-06	8.13e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CTNNB1—colon cancer	3.91e-06	8.1e-05	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	3.89e-06	8.05e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—colon cancer	3.89e-06	8.05e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TGFB1—colon cancer	3.88e-06	8.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—PIK3CA—colon cancer	3.83e-06	7.94e-05	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.83e-06	7.93e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CDKN1A—colon cancer	3.82e-06	7.92e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—colon cancer	3.8e-06	7.88e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CTNNB1—colon cancer	3.8e-06	7.87e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDKN1A—colon cancer	3.71e-06	7.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—PIK3CA—colon cancer	3.68e-06	7.62e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—AKT1—colon cancer	3.66e-06	7.59e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PPARG—colon cancer	3.66e-06	7.58e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.65e-06	7.56e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EP300—colon cancer	3.63e-06	7.53e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	3.63e-06	7.52e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—colon cancer	3.59e-06	7.44e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—AKT1—colon cancer	3.57e-06	7.4e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—colon cancer	3.54e-06	7.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—AKT1—colon cancer	3.54e-06	7.34e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SRC—colon cancer	3.53e-06	7.33e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EP300—colon cancer	3.53e-06	7.32e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—colon cancer	3.44e-06	7.13e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SRC—colon cancer	3.43e-06	7.11e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ABCB1—colon cancer	3.43e-06	7.1e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—colon cancer	3.4e-06	7.05e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—colon cancer	3.4e-06	7.05e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TYMS—colon cancer	3.37e-06	6.98e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR3—colon cancer	3.36e-06	6.97e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—colon cancer	3.35e-06	6.94e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—colon cancer	3.33e-06	6.9e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—EP300—colon cancer	3.31e-06	6.87e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.31e-06	6.86e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—colon cancer	3.3e-06	6.84e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PIK3CA—colon cancer	3.3e-06	6.84e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CTNNB1—colon cancer	3.25e-06	6.73e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ABCB1—colon cancer	3.24e-06	6.71e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.23e-06	6.69e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SRC—colon cancer	3.22e-06	6.68e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—colon cancer	3.19e-06	6.61e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TYMS—colon cancer	3.18e-06	6.59e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1A—colon cancer	3.17e-06	6.57e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—colon cancer	3.17e-06	6.56e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFB1—colon cancer	3.16e-06	6.55e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—colon cancer	3.14e-06	6.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—AKT1—colon cancer	3.13e-06	6.49e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—colon cancer	3.1e-06	6.43e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—colon cancer	3.1e-06	6.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—APC—colon cancer	3.09e-06	6.4e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—colon cancer	3.09e-06	6.4e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—colon cancer	3.09e-06	6.4e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—colon cancer	3.05e-06	6.32e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.03e-06	6.29e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.02e-06	6.25e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—EP300—colon cancer	3.02e-06	6.25e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—colon cancer	3.01e-06	6.24e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—AKT1—colon cancer	3.01e-06	6.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CTNNB1—colon cancer	3e-06	6.21e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ABCB1—colon cancer	2.97e-06	6.15e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ABCB1—colon cancer	2.95e-06	6.12e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SRC—colon cancer	2.93e-06	6.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1A—colon cancer	2.93e-06	6.07e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—colon cancer	2.93e-06	6.07e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TYMS—colon cancer	2.92e-06	6.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—BRAF—colon cancer	2.9e-06	6.02e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TYMS—colon cancer	2.9e-06	6.01e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—colon cancer	2.88e-06	5.97e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—colon cancer	2.88e-06	5.96e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—colon cancer	2.84e-06	5.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—colon cancer	2.82e-06	5.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—EP300—colon cancer	2.79e-06	5.77e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—colon cancer	2.71e-06	5.61e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—AKT1—colon cancer	2.69e-06	5.58e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PIK3CA—colon cancer	2.69e-06	5.57e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—colon cancer	2.67e-06	5.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—colon cancer	2.66e-06	5.51e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—colon cancer	2.62e-06	5.43e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PIK3CA—colon cancer	2.61e-06	5.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—colon cancer	2.61e-06	5.4e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—colon cancer	2.6e-06	5.39e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—EP300—colon cancer	2.57e-06	5.32e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—colon cancer	2.54e-06	5.26e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.54e-06	5.26e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—colon cancer	2.49e-06	5.16e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—PIK3CA—colon cancer	2.45e-06	5.08e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.45e-06	5.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PIK3CA—colon cancer	2.44e-06	5.06e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ABCB1—colon cancer	2.44e-06	5.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—colon cancer	2.43e-06	5.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—colon cancer	2.43e-06	5.03e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—colon cancer	2.42e-06	5.02e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—colon cancer	2.42e-06	5.01e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—colon cancer	2.39e-06	4.96e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—EP300—colon cancer	2.39e-06	4.96e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—colon cancer	2.38e-06	4.94e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—colon cancer	2.37e-06	4.92e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—colon cancer	2.27e-06	4.7e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—colon cancer	2.26e-06	4.68e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—colon cancer	2.25e-06	4.67e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.24e-06	4.65e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—colon cancer	2.24e-06	4.65e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.23e-06	4.63e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PIK3CA—colon cancer	2.23e-06	4.62e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—AKT1—colon cancer	2.2e-06	4.55e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—EP300—colon cancer	2.18e-06	4.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CASP3—colon cancer	2.18e-06	4.51e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—AKT1—colon cancer	2.13e-06	4.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—colon cancer	2.12e-06	4.39e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.11e-06	4.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CTNNB1—colon cancer	2.1e-06	4.35e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—colon cancer	2.07e-06	4.28e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ABCB1—colon cancer	2.06e-06	4.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—colon cancer	2.06e-06	4.28e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PIK3CA—colon cancer	2.06e-06	4.27e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—colon cancer	2.05e-06	4.26e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1A—colon cancer	2.05e-06	4.25e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—colon cancer	2.03e-06	4.2e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—AKT1—colon cancer	2e-06	4.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—AKT1—colon cancer	2e-06	4.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EP300—colon cancer	1.95e-06	4.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—colon cancer	1.91e-06	3.95e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PIK3CA—colon cancer	1.9e-06	3.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—colon cancer	1.9e-06	3.93e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—colon cancer	1.88e-06	3.89e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—colon cancer	1.85e-06	3.83e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—colon cancer	1.82e-06	3.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—AKT1—colon cancer	1.82e-06	3.78e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—colon cancer	1.8e-06	3.73e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—colon cancer	1.77e-06	3.67e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PIK3CA—colon cancer	1.77e-06	3.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—colon cancer	1.7e-06	3.52e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—colon cancer	1.7e-06	3.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—colon cancer	1.7e-06	3.51e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—AKT1—colon cancer	1.68e-06	3.49e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—colon cancer	1.62e-06	3.37e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—colon cancer	1.62e-06	3.35e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PIK3CA—colon cancer	1.61e-06	3.34e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ABCB1—colon cancer	1.59e-06	3.3e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—colon cancer	1.57e-06	3.25e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—colon cancer	1.57e-06	3.24e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.56e-06	3.24e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—EP300—colon cancer	1.56e-06	3.23e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—AKT1—colon cancer	1.55e-06	3.21e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—EP300—colon cancer	1.47e-06	3.05e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—AKT1—colon cancer	1.45e-06	3e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PIK3CA—colon cancer	1.44e-06	2.99e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—colon cancer	1.44e-06	2.98e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—colon cancer	1.42e-06	2.93e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—colon cancer	1.4e-06	2.89e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—EP300—colon cancer	1.35e-06	2.8e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—EP300—colon cancer	1.34e-06	2.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—colon cancer	1.33e-06	2.77e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—colon cancer	1.33e-06	2.76e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—AKT1—colon cancer	1.32e-06	2.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—AKT1—colon cancer	1.18e-06	2.44e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—EP300—colon cancer	1.18e-06	2.44e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PIK3CA—colon cancer	1.15e-06	2.39e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—colon cancer	1.13e-06	2.34e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—EP300—colon cancer	1.11e-06	2.3e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—colon cancer	1.11e-06	2.3e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PIK3CA—colon cancer	1.09e-06	2.26e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PIK3CA—colon cancer	1e-06	2.07e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PIK3CA—colon cancer	9.94e-07	2.06e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—AKT1—colon cancer	9.43e-07	1.95e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—EP300—colon cancer	9.4e-07	1.95e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—AKT1—colon cancer	8.91e-07	1.85e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—colon cancer	8.72e-07	1.81e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PIK3CA—colon cancer	8.71e-07	1.8e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PIK3CA—colon cancer	8.21e-07	1.7e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—AKT1—colon cancer	8.17e-07	1.69e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—AKT1—colon cancer	8.12e-07	1.68e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—EP300—colon cancer	7.25e-07	1.5e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—AKT1—colon cancer	7.11e-07	1.47e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PIK3CA—colon cancer	6.95e-07	1.44e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—AKT1—colon cancer	6.7e-07	1.39e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—AKT1—colon cancer	5.68e-07	1.18e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PIK3CA—colon cancer	5.37e-07	1.11e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—AKT1—colon cancer	4.38e-07	9.08e-06	CbGpPWpGaD
